Citi maintains Novo Nordisk B at Buy

  • Investing.com
Citi maintains Novo Nordisk B at Buy

A Citi analyst maintained Novo Nordisk B (CSE: NOVOb) at Buy and a price target of $1200.00.

Prior to this rating, Novo Nordisk B had 14 buy ratings, 4 hold ratings, and 4 sell ratings.

For consensus analyst estimates and price targets on Novo Nordisk B, click here. For more news on Novo Nordisk B, click here.

Novo Nordisk B's stock price closed at $1.0. They are down -99.9% in the last month and up 43.0% in the last 12 months.

According to Investing Pro, Novo Nordisk B's fair value is $887.4, an upside of -16.6%. Novo Nordisk B's fair value comes with a low degree of uncertainty, according to InvestingPro.

Check out Novo Nordisk B's recent earnings performance and financials here.

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or

100